Private company · employee equity guide
What is Saliogen Therapeutics stock worth?
SalioGen Therapeutics is a biotechnology company on a mission to accelerate the impact of genetic medicine for patients using its novel Gene CodingTM technology. Gene Coding is a non-viral method of integrating large or multiple whole genes into the genome at precise locations through transposition. This mechanism does not induce double-strand breaks or use guide RNA and has the potential to overcome the safety risks and limitations of other genetic medicine approaches., , SalioGen's lead programs focus on one-time treatments for Stargardt disease and cystic fibrosis. The company is also devel
Estimated share price
Saliogen Therapeutics has an observed estimated price: most recent data 2026-09-15, daily history back to 2023-11-29.
Estimated from live trades and accepted bids across employer liquidity programs, institutional trades, broker trades, and pre-IPO marketplaces. Private shares are illiquid and transfer-restricted; estimates are educational, not an offer or advice. The preview above is blurred and illustrative. How this is calculated
About Saliogen Therapeutics
- Employees
- 50
- Founded
- 2020
- Website
- saliogen.com
Weighing a Saliogen Therapeutics offer?
Upload the offer letter to see what the equity is approximately worth at today's estimated price. No account needed.
X-ray an offerLeaving Saliogen Therapeutics? Mind the window.
If you hold options, leaving usually starts a post-termination exercise clock, often 90 days. Miss it and vested options can expire worthless; exercise blindly and you may owe real money (including possible AMT) on shares you can't yet sell. Neither panic nor autopilot is a plan. Knowing your window, your exercise cost, and the current estimated price is.
Saliogen Therapeutics equity, answered plainly
Is Saliogen Therapeutics a public company?
No. Saliogen Therapeutics is privately held, which is exactly why its share price doesn't show up in your brokerage app. The company (founded in 2020, with roughly 50 employees) remains private even at that scale. Its shares still change hands between eligible buyers and sellers on the secondary market, producing an observable estimated price.
What is Saliogen Therapeutics' stock price?
Saliogen Therapeutics has an observed estimated share price from secondary-market activity, updated as new data is observed. Its observed price history runs back to 2023-11-29. ExitCue members see the current estimate and its full history free, along with what their own grants are approximately worth at that price.
Can you sell Saliogen Therapeutics stock before an IPO?
Sometimes. Private-share sales depend on Saliogen Therapeutics' transfer restrictions, rights of first refusal, and whether the company runs tender offers or permits secondary sales. Your grant documents and the company's policies govern, but "hard to sell today" is not the same as "worth zero."
What happens to my Saliogen Therapeutics options if I leave?
Most option grants have a post-termination exercise window, commonly 90 days, sometimes longer, after which unexercised options expire worthless. The exact terms are in your grant documents. ExitCue reads those documents, tracks the deadline, and reminds you before the window closes.
How much is my Saliogen Therapeutics equity worth?
Multiply what you hold by the estimated share price, separating vested from unvested, and netting out strike prices for options. That's precisely the arithmetic ExitCue does for you, continuously, at the current observed estimate. It's an educational estimate, not a guarantee, and a far better anchor than the $0 the internet suggests.
What's the difference between Saliogen Therapeutics' 409A valuation and what its shares trade at?
The 409A is a tax-compliance appraisal, usually conservative, used to set option strike prices. Secondary-market pricing reflects what buyers and sellers actually agree to. The two frequently differ, which is why evaluating an offer on the 409A alone undersells (or oversells) it.
When will Saliogen Therapeutics IPO?
Unless Saliogen Therapeutics has publicly announced a listing, nobody knows, including the people who sound confident on forums. The practical upside of secondary markets is that you don't have to wait for an IPO to know approximately what the shares trade at.
Do my unvested Saliogen Therapeutics RSUs count for anything?
Unvested equity isn't yours yet, but it has an estimable value and a schedule. Seeing vested and unvested value separately, in dollars at the current estimated price, turns "some RSUs" into a number you can plan around.
General educational information, not advice about your specific situation. Grant terms vary; your documents govern.
Work out what your Saliogen Therapeutics equity is worth
These calculators take your own numbers and need no account.
- Option exercise costShares times strike: what exercising would cost, plus the estimated spread from your own value estimate.
- Vesting scheduleYour upcoming vest dates and cumulative vested shares from your start date, cliff, length, and frequency.
- Private stock scenarioEstimated value of your equity at low, mid, and high per-share scenarios you choose yourself.
New to this? Learn explains grant types, vesting and cliffs, and where an estimated share price comes from — in plain language.
Other private companies with observed prices
Company logos provided by Brandfetch.